News

Filter

Current filters:

PharmaceuticalAlgeta

1 to 9 of 22 results

Bayer takes advantage of low interest rates, issuing 2 billion euros of bonds

Bayer takes advantage of low interest rates, issuing 2 billion euros of bonds

22-01-2014

German pharma and life sciences group Bayer says it is taking advantage of currently low interest rates…

AlgetaBayerFinancialMergers & AcquisitionsPharmaceutical

Bayer confirms plans to acquire Norway’s Algeta

Bayer confirms plans to acquire Norway’s Algeta

19-12-2013

German drugs and chemicals major Bayer has officially announced its intention to acquire Norwegian pharmaceutical…

AlgetaBayerGermanyMergers & AcquisitionsNorwayOncologyPharmaceuticalXofigo

Norway’s Algeta confirms takeover bid approach from Bayer

Norway’s Algeta confirms takeover bid approach from Bayer

26-11-2013

In response to recent media commentary, the board of directors of Norway’s Algeta this morning confirmed…

AlgetaBayerMergers & AcquisitionsNorwayOncologyPharmaceuticalXofigo

EU approval for Bayer’s prostate cancer drug Xofigo

EU approval for Bayer’s prostate cancer drug Xofigo

15-11-2013

The European Commission has granted marketing authorization for German drug and chemical major Bayer’s…

AlgetaBayerEuropeOncologyPharmaceuticalRegulationXofigo

EMA unit backs approval of Bayer's radium-233

EMA unit backs approval of Bayer's radium-233

20-09-2013

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended…

AlgetaBayerEuropeOncologyPharmaceuticalradium-223 dichlorideRegulationXofigo

Positive results for Bayer's prostate cancer drug

18-07-2013

German drug major Bayer (BAYN: DE) has announced positive results of a Phase III study of its drug radium…

AlgetaBayerEuropeMen's HealthPharmaceuticalResearchXofigo

First sales of Xofigo triggers 50 million-euro milestone payment to Algeta from Bayer

30-05-2013

Norway's Algeta (OSE: ALGETA) announced today (May 30) that Xofigo (radium Ra 223 dichloride) injection…

AlgetaBayerFinancialMarkets & MarketingNorth AmericaPharmaceuticalXofigo

Fast FDA approval for Bayer's new drug for advanced prostate cancer, Xofigo

16-05-2013

The US Food and Drug Administration yesterday (May 15) approved Xofigo (radium Ra 223 dichloride, initially…

AlgetaAstellas PharmaBayerNorth AmericaOncologyPharmaceuticalRegulationXofigo

1 to 9 of 22 results

Back to top